sábado, 1 de junio de 2019

What can a patient registry tell us about the course of idiopathic pulmonary fibrosis? - On Health

What can a patient registry tell us about the course of idiopathic pulmonary fibrosis? - On Health

Dr. Laurie Snyder

Dr. Laurie Snyder

Dr. Laurie Snyder is an Associate Professor of Medicine in the division of Pulmonary and Critical Care at Duke University and a member of the Duke Clinical Research Institute. Her clinical and research interests are in advanced lung disease, immunology and lung transplantation.


What can a patient registry tell us about the course of idiopathic pulmonary fibrosis?

Research published today in Respiratory Research presents findings from the IPF-PRO Registry, a nationwide US registry collecting data on the clinical course of Idiopathic pulmonary fibrosis (IPF) and its impact on patients.
Idiopathic pulmonary fibrosis, or IPF, is a rare, debilitating lung disease that mainly affects individuals over the age of 60. IPF is characterized by progressive fibrosis (scarring) of the lungs, which leads to a loss of lung volume and an impaired ability of the lungs to exchange gases. Ultimately IPF is fatal.

No hay comentarios:

Publicar un comentario